Peptides / Recovery and repair

Natural peptide · 84 amino acids · 9,425 Da

PTH 1-84 (parathyroid hormone)

ApprovedNot banned in sport

PTH 1-84 (Natpara) is the full-length human parathyroid hormone, approved in the US for hypoparathyroidism but no longer made, and withdrawn in the EU. Studies in people tested it mostly on bone, blood calcium and quality of life, and tracked side effects. PepBank shows 270 results on parathyroid hormone from 36 studies in people, and 148 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as ALX1-11, NPSP558, Natpar, Natpara, PTH(1-84), Parathyroid hormone and 2 more

First 40 of 84 amino acids0 changed amino acids

Evidence level: Large trials in people270 of 418 results come from studies in people, including randomized trials.

Results in people

270

65% of 418 results

Results in animals

148

35% of 418 results

Results in lab cells

0% of 418 results

From computer models

0% of 418 results

Overview

PTH 1-84 (parathyroid hormone) at a glance

What it is	Natural peptide, 84 amino acids
Approval	Approved in the US (Natpara, 2015)
In sport	Not listed as banned by WADA
Studies	56 studies with results. All of them gave parathyroid hormone, with 418 results. 270 in people148 in animals
Best study in people	Randomized controlled trial with 134 people (2013)
Clinical trials	31 registered: 0 active or planned, 17 with posted results
Community use	Historical Natpara initiation in adults with hypoparathyroidism inadequately controlled with calcium and active vitamin D alone

The science

What is parathyroid hormone?

This record covers intact human PTH(1-84), including the historical recombinant Natpara/Natpar product.

Amino acids in one chain

The history of parathyroid hormone

1975
The oldest paper on parathyroid hormone in PepBank is from 1975.
2004May
A registered trial of parathyroid hormone started (NCT00473265).
2015January
FDA approved Natpara for adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.

PTH 1-84 (parathyroid hormone) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 84 amino acidsFrom the first amino acid to the last

S1VS−EI5QLMHN10LG+KHL15NSM−E+R20V−EWL+R25+K+KLQ−D30VHNFV35ALGAP40LAP+R−D45AGSQ+R50P+R+K+K−E55−DNVLV60−ESH−E+K65SLG−EA70−D+KA−DV75NVLT+K80A+KSQ

Darker means more water-repelling+ and − show charge in the body

Structure

PTH 1-84 (parathyroid hormone) is a natural peptide of 84 amino acids, with no ring, no changed amino acids.

Molecular weight

9,425 g/mol

CAS number

9002-64-6

Target

Parathyroid hormone 1 receptor (gene PTH1R): agonistEvidence: UniProt P01270 function and Q03431 receptor annotation

Development

Highest phase: past the trial stage (see status).

Identifiers

ChEMBL CHEMBL2108078, UNII N19A0T0E5J, DrugBank DB05829

See charge, composition and 3D structure on the Scientific page

The evidence

What parathyroid hormone studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people270 of 418 results come from studies in people, including randomized trials.

Bones and joints

292 results · 154 in people · 138 animal

In hypoparathyroidism, PTH increased undercarboxylated osteocalcin more than placebo. The Journal of clinical endocrinology and metabolism, 2015

Top results

In hypoparathyroidism, PTH increased undercarboxylated osteocalcin more than placebo. (The Journal of clinical endocrinology and metabolism, 2015)
In healthy postmenopausal volunteers, rhPTH(1-84) increased serum ionized calcium dose dependently. (Clinical pharmacology and therapeutics, 1997)
In postmenopausal women, PTH increased spine bone density by 2.1% versus placebo at 12 months. (The Journal of clinical endocrinology and metabolism, 2008)

Salt, water and minerals

38 results · 36 in people · 2 animal

In adults with hypoparathyroidism, more rhPTH(1-84) recipients than placebo recipients reduced both supplements by at least 50% while maintaining blood calcium. The lancet. Diabetes & endocrinology, 2013

Top results

In adults with hypoparathyroidism, more rhPTH(1-84) recipients than placebo recipients reduced both supplements by at least 50% while maintaining blood calcium. (The lancet. Diabetes & endocrinology, 2013)
In osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in ionized calcium changes. (Calcified tissue international, 2009)
In adults with chronic hypoparathyroidism, twice-daily versus once-daily rhPTH(1-84) showed no pharmacodynamic differences considered clinically meaningful. (JBMR plus, 2023)

Daily life and fitness

19 results · 19 in people

In chronic hypoparathyroidism, PTH did not significantly improve SF-36 scores versus placebo at week 24. The Journal of clinical endocrinology and metabolism, 2018

Top results

In chronic hypoparathyroidism, PTH did not significantly improve SF-36 scores versus placebo at week 24. (The Journal of clinical endocrinology and metabolism, 2018)
In elderly women with osteoporosis and pelvic fractures, PTH improved mobility test performance versus control. (The Journal of bone and joint surgery. American volume, 2011)
In symptomatic chronic hypoparathyroidism, rhPTH(1-84) reduced symptom scores more than placebo at week 26. (European journal of endocrinology, 2025)

Kidneys and bladder

10 results · 9 in people · 1 animal

In adults with chronic hypoparathyroidism, twice-daily rhPTH(1-84) reduced urinary calcium numerically more than once-daily dosing. JBMR plus, 2023

Top results

In adults with chronic hypoparathyroidism, twice-daily rhPTH(1-84) reduced urinary calcium numerically more than once-daily dosing. (JBMR plus, 2023)
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), mean urinary calcium excretion was within the reference range at treatment end. (Endocrine practice, 2024)
In people with hypoparathyroidism, urinary calcium was mostly unchanged after 24 months of PTH treatment. (Osteoporosis international, 2010)

Hormones

6 results · 6 in people

In patients with hypoparathyroidism, PTH reduced calcium supplement doses by 75% versus placebo. Journal of bone and mineral research, 2011

Top results

In patients with hypoparathyroidism, PTH reduced calcium supplement doses by 75% versus placebo. (Journal of bone and mineral research, 2011)
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), mean calcium supplement doses were maintained throughout the study. (Endocrine practice, 2024)
In people with hypoparathyroidism, calcium supplement requirements fell during PTH treatment. (Osteoporosis international, 2010)

Blood sugar

4 results · 4 in people

In osteoporotic women, PTH decreased blood glucose versus calcium and colecalcipherol alone. Bone, 2015

Top results

In osteoporotic women, PTH decreased blood glucose versus calcium and colecalcipherol alone. (Bone, 2015)
In osteoporotic women, PTH did not affect insulin secretion, insulin resistance, or pancreatic beta-cell function versus calcium and colecalcipherol alone. (Bone, 2015)
In osteoporotic women, PTH did not influence adipokine production versus calcium and colecalcipherol alone. (Bone, 2015)

Parathyroid hormone has 279 linked papers. PepBank read up to 120 of the most-cited studies that gave it to people, up to 20 other studies, and the main trials.

All 56 parathyroid hormone studies by area Open the Scientific page

Key parathyroid hormone studies

Studies in people come first, then studies in animals and in the lab.

People
Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study
Mannstadt et al. 2013 · The lancet. Diabetes & endocrinology · 134 people · cited by 176
4 results
People
rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes
Brandi et al. 2025 · European journal of endocrinology · 93 people · cited by 2
4 results
People
The Effect of Treatment With PTH on Undercarboxylated Osteocalcin and Energy Metabolism in Hypoparathyroidism
Harsløf et al. 2015 · The Journal of clinical endocrinology and metabolism · 58 people · cited by 18
4 results
People
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling
Black et al. 2008 · The Journal of clinical endocrinology and metabolism · 50 people · cited by 41
8 results
People
A Phase I Randomized Trial of Once-Daily Versus Twice-Daily Recombinant Human Parathyroid Hormone (1-84) for Hypoparathyroidism
Ing et al. 2023 · JBMR plus · 33 people · cited by 2
10 results

All 56 PTH 1-84 (parathyroid hormone) studies

PTH 1-84 clinical trials

ClinicalTrials.gov lists 31 trials of parathyroid hormone. 0 are active or planned, and 17 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Sequential Treatment of Postmenopausal Women With Primary Osteoporosis (FP-001-IM)

Phase 3completed407 people

Use of NPSP558 in the Treatment of Hypoparathyroidism

Phase 3completed124 people

A Study to Learn if Recombinant Human Parathyroid Hormone [rhPTH(1-84)] Can Improve Symptoms and Metabolic Control in Adults With Hypoparathyroidism (BALANCE)

Phase 4completed93 people

All 20 PTH 1-84 (parathyroid hormone) trials

Status and safety

Is parathyroid hormone approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Withdrawn

Withdrawn.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US (Natpara, 2015). The FDA label for Natpara says: “Adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism” No central EU authorisation (EMA). Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

PTH 1-84 side effects and safety

PepBank has 48 safety results from studies of parathyroid hormone. 34 of them come from studies in people.

Safety results from studies (48)

In osteoporotic women, hypercalciuria occurred more often with PTH than with placebo. (Annals of internal medicine, 2007)
In adults with hypoparathyroidism, six rhPTH(1-84) patients and seven placebo patients discontinued before study end. (The lancet. Diabetes & endocrinology, 2013)
In hypoparathyroidism, PTH increased hypercalcemic episodes compared with placebo. (The Journal of clinical endocrinology and metabolism, 2015)
In postmenopausal women, high urinary calcium occurred more often with PTH and HT than HT alone. (Calcified tissue international, 2008)
In adults with chronic hypoparathyroidism receiving rhPTH(1-84), no new safety findings were observed. (JBMR plus, 2023)
In symptomatic chronic hypoparathyroidism patients receiving rhPTH(1-84), no new safety signals were identified. (European journal of endocrinology, 2025)
In adults with chronic hypoparathyroidism receiving extended rhPTH(1-84), four adverse events were considered treatment related. (Endocrine practice, 2024)
In hypoparathyroidism, 92% reported treatment-emergent adverse events during PTH treatment. (Endocrine practice, 2016)
In hypoparathyroidism, 74% receiving PTH 50 μg/d reported treatment-emergent adverse events. (Clinical therapeutics, 2017)
In women with osteoporosis, bone produced during PTH treatment had normal structure and mineralization without abnormal histology. (Bone, 2009)
In osteoporotic women, PTH(1-84) and PTH(1-34) did not differ in ionized calcium changes. (Calcified tissue international, 2009)
In osteoporotic women, PTH treatment was generally well tolerated. (The Journal of clinical endocrinology and metabolism, 2003)
Patients receiving PTH reduced supplements without developing low blood calcium. (Journal of bone and mineral research, 2011)
In hypoparathyroidism, 71% of PTH-treated patients had high blood calcium without symptoms. (Journal of bone and mineral research, 2013)
In osteoporotic women, no significant adverse events were reported in the PTH trial. (Bone, 2015)
In women with osteoporosis, PTH was well tolerated over 36 months. (Current medical research and opinion, 2010)
In osteoporotic women, high blood calcium occurred more often with PTH than with placebo. (Annals of internal medicine, 2007)
In osteoporotic women, nausea occurred more often with PTH than with placebo. (Annals of internal medicine, 2007)
In adults with hypoparathyroidism, adverse-event proportions were described as similar with rhPTH(1-84) and placebo. (The lancet. Diabetes & endocrinology, 2013)
In adults with hypoparathyroidism, serious adverse-event proportions were described as similar with rhPTH(1-84) and placebo. (The lancet. Diabetes & endocrinology, 2013)
In postmenopausal women, high blood calcium occurred more often with PTH and HT than HT alone. (Calcified tissue international, 2008)
In postmenopausal women, nausea occurred more often with PTH and HT than HT alone. (Calcified tissue international, 2008)
In postmenopausal women, vomiting occurred more often with PTH and HT than HT alone. (Calcified tissue international, 2008)
In postmenopausal women, dizziness occurred more often with PTH and HT than HT alone. (Calcified tissue international, 2008)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
50 μg per day, titrated to 75 μg or 100 μg	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 134	Mannstadt 2013
25-100 µg/day	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 93	Brandi 2025
100 μg/d	Human	human	Not reported	24 weeks	Randomized trial in people · n = 58	Harsløf 2015
100 mug daily for 1 month, then weekly for 11 months	Human	human	subcutaneous	12 months	Randomized trial in people · n = 50	Black 2008
25 μg twice daily, 50 μg twice daily, or 100 μg once daily	Human	human	subcutaneous	1 day	Randomized trial in people · n = 33	Ing 2023
100 mug daily	Human	human	subcutaneous	18 months	Randomized trial in people	Greenspan 2007
100 microg daily	Human	human	injection	Not reported	Randomized trial in people	Fogelman 2008
100 mug daily	Human	human	subcutaneous	1 month	Randomized trial in people · n = 50	Black 2008
100 microg daily	Human	human	Not reported	12 months	Randomized trial in people · n = 179	Black 2003
50 µg/day titrated to 75 and then 100 µg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 124	Clarke 2017
50 μg/d titrated up to 100 μg/d	Human	human	Not reported	Not reported	Randomized trial in people · n = 122	Vokes 2018
100 μg daily	Human	human	subcutaneous injection	24 weeks	Randomized trial in people · n = 81	Quesada-Gómez 2011
100 µg once daily	Human	human	injection	Not reported	Randomized trial in people · n = 65	Peichl 2011
100 µg daily	Human	human	Not reported	24 weeks	Randomized trial in people · n = 62	Sikjaer 2011
100 μg/d	Human	human	subcutaneous	6 months	Randomized trial in people · n = 62	Sikjaer 2014
100 µg/day	Human	human	subcutaneous	24 weeks	Randomized trial in people · n = 44	Sikjaer 2012
100 μg a day	Human	human	Not reported	6 months	Randomized trial in people · n = 42	van 2023
100 µg/d	Human	human	subcutaneous in the thigh	6 months	Randomized trial in people · n = 38	Sikjaer 2013
100 μg daily	Human	human	injection	6 months	Randomized trial in people	Thomsen 2026
50 μg/day escalated to 75 and then 100 μg/day if needed	Human	human	Not reported	24 weeks	Trial in people without random groups · n = 24	Lakatos 2016
50 μg/d	Human	human	subcutaneous	8 weeks	Trial in people without random groups · n = 23	Bilezikian 2017
25 μg/d	Human	human	subcutaneous	8 weeks	Trial in people without random groups · n = 19	Bilezikian 2017
100 microg/d	Human	human	Not reported	1 year	Trial in people without random groups · n = 63	Garnero 2008
100 µg every other day	Human	human	subcutaneous	24 months	Trial in people without random groups · n = 30	Rubin 2010
100 microg	Human	human	Not reported	18 months	Trial in people without random groups · n = 16	Recker 2009
100 mcg	Human	human	injection	single dose	Trial in people without random groups · n = 10	Piemonte 2009
50, 75, or 100 microg	Human	human	Not reported	1 year	Trial in people without random groups	Rittmaster 2000
50, 75, or 100 microg daily	Human	human	subcutaneous	12 months	Trial in people without random groups	Hodsman 2003
100 microg daily	Human	human	subcutaneous	3 months	Trial in people without random groups	Hodsman 2003
0.02 to 2.0 micrograms.kg-1	Human	human	subcutaneous	single dose	Trial in people without random groups	Schwietert 1997
2.0 to 5.0 micrograms.kg-1	Human	human	subcutaneous	single dose	Trial in people without random groups	Schwietert 1997
>2.5 micrograms.kg-1	Human	human	subcutaneous	single dose	Trial in people without random groups	Schwietert 1997
> or = 1.5 micrograms.kg-1	Human	human	subcutaneous	single dose	Trial in people without random groups	Schwietert 1997
0.02 to 5.0 micrograms.kg-1	Human	human	subcutaneous	single dose	Trial in people without random groups	Schwietert 1997
100 µg once daily	Human	human	Not reported	36 months	Trial in people without random groups	Zanchetta 2010
100 mug/d	Human	human	subcutaneous	1 yr	Observational study · n = 119	Bauer 2006
100 microg/kg/day, 5 days/week	Animal	rat	Not reported	Not reported	Study in live animals · n = 12	Rhee 2004
1.1, 3.3, 10, or 30 nmol/kg/day	Animal	rat	Not reported	30 days	Study in live animals	Ejersted 1993
10, 50, 150 microg/kg/day	Animal	rat	subcutaneous	2 years	Study in live animals	Jolette 2006
50 and 150 microg/kg/day	Animal	rat	subcutaneous	2 years	Study in live animals	Jolette 2006

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

This record describes one historical US Natpara starting regimen for adults with hypoparathyroidism. It reports official label information.

Reported routines and cautions

What people use it for

Historical Natpara initiation in adults with hypoparathyroidism inadequately controlled with calcium and active vitamin D aloneS1

Reported regimens

Regimens that community sources report for Parathyroid hormone (PTH 1-84). Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Historical Natpara initiation in adults with hypoparathyroidism inadequately controlled with calcium and active vitamin D aloneOfficial label dosing of an approved product	subcutaneous injectionInject into the thigh. Alternate thighs each day.	50 mcg per dose	once daily	Not stated	Single official US label source.	S1

Cautions

The label reports osteosarcoma in rats. It cannot exclude a human risk. Avoid use in patients with increased baseline osteosarcoma risk.S1
The label warns about severe hypercalcemia and hypocalcemia, including severe hypocalcemia after interruption. It contraindicates use with known hypersensitivity to product components.S1
The label did not establish pediatric safety or efficacy. It did not study acute postsurgical hypoparathyroidism or hypoparathyroidism caused by calcium-sensing receptor mutations.S1
The historical label required a restricted REMS program. Digoxin use requires additional monitoring because hypercalcemia can increase digoxin toxicity risk.S1

Status notes

The EU withdrew Natpar on 1 July 2026 after the holder reported unresolved supply issues.S2

Community sources

S1Natpara US prescribing information (opens in a new tab)dailymed.nlm.nih.gov
S2EMA regulatory information (opens in a new tab)ema.europa.eu

plus 1 seller page (not linked)

Gaps

This record establishes one selected official-label use. It does not establish a separate non-vendor community regimen. It covers Natpara initiation only. Maintenance titration and other formulations require their own label assessment.

Questions and more

Ask a question about parathyroid hormone

The answer links to every study it uses.

What does the evidence say about parathyroid hormone?Is parathyroid hormone tested in people?Compare with Teriparatide (PTH 1-34)Compare with Calcitonin-salmon

Sources

Database: PepBank data for parathyroid hormone (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about parathyroid hormone

PTH 1-84 (parathyroid hormone)

ApprovedNot banned in sport

Also known as ALX1-11, NPSP558, Natpar, Natpara, PTH(1-84), Parathyroid hormone and 2 more

What it is

Natural peptide, 84 amino acids

Approval

Approved in the US (Natpara, 2015)

In sport

Not listed as banned by WADA

Studies

56 studies with results. All of them gave parathyroid hormone, with 418 results.
270 in people148 in animals

Best study in people

Randomized controlled trial with 134 people (2013)

Clinical trials

31 registered: 0 active or planned, 17 with posted results

Community use

Historical Natpara initiation in adults with hypoparathyroidism inadequately controlled with calcium and active vitamin D alone

Dose as reported

Class

Species

Route

Duration

Design

Source

50 μg per day, titrated to 75 μg or 100 μg

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 134

Mannstadt 2013

25-100 µg/day

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 93

Brandi 2025

100 μg/d

Human

human

Not reported

24 weeks

Randomized trial in people · n = 58

Harsløf 2015

100 mug daily for 1 month, then weekly for 11 months

Human

human

subcutaneous

12 months

Randomized trial in people · n = 50

Black 2008

25 μg twice daily, 50 μg twice daily, or 100 μg once daily

Human

human

subcutaneous

1 day

Randomized trial in people · n = 33

Ing 2023

100 mug daily

Human

human

subcutaneous

18 months

Randomized trial in people

Greenspan 2007

100 microg daily

Human

human

injection

Not reported

Randomized trial in people

Fogelman 2008

100 mug daily

Human

human

subcutaneous

1 month

Randomized trial in people · n = 50

Black 2008

100 microg daily

Human

human

Not reported

12 months

Randomized trial in people · n = 179

Black 2003

50 µg/day titrated to 75 and then 100 µg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 124

Clarke 2017

50 μg/d titrated up to 100 μg/d

Human

human

Not reported

Randomized trial in people · n = 122

Vokes 2018

100 μg daily

Human

human

subcutaneous injection

24 weeks

Randomized trial in people · n = 81

Quesada-Gómez 2011

100 µg once daily

Human

human

injection

Not reported

Randomized trial in people · n = 65

Peichl 2011

100 µg daily

Human

human

Not reported

24 weeks

Randomized trial in people · n = 62

Sikjaer 2011

100 μg/d

Human

human

subcutaneous

6 months

Randomized trial in people · n = 62

Sikjaer 2014

100 µg/day

Human

human

subcutaneous

24 weeks

Randomized trial in people · n = 44

Sikjaer 2012

100 μg a day

Human

human

Not reported

6 months

Randomized trial in people · n = 42

van 2023

100 µg/d

Human

human

subcutaneous in the thigh

6 months

Randomized trial in people · n = 38

Sikjaer 2013

100 μg daily

Human

human

injection

6 months

Randomized trial in people

Thomsen 2026

50 μg/day escalated to 75 and then 100 μg/day if needed

Human

human

Not reported

24 weeks

Trial in people without random groups · n = 24

Lakatos 2016

50 μg/d

Human

human

subcutaneous

8 weeks

Trial in people without random groups · n = 23

Bilezikian 2017

25 μg/d

Human

human

subcutaneous

8 weeks

Trial in people without random groups · n = 19

Bilezikian 2017

100 microg/d

Human

human

Not reported

1 year

Trial in people without random groups · n = 63

Garnero 2008

100 µg every other day

Human

human

subcutaneous

24 months

Trial in people without random groups · n = 30

Rubin 2010

100 microg

Human

human

Not reported

18 months

Trial in people without random groups · n = 16

Recker 2009

100 mcg

Human

human

injection

single dose

Trial in people without random groups · n = 10

Piemonte 2009

50, 75, or 100 microg

Human

human

Not reported

1 year

Trial in people without random groups

Rittmaster 2000

50, 75, or 100 microg daily

Human

human

subcutaneous

12 months

Trial in people without random groups

Hodsman 2003

100 microg daily

Human

human

subcutaneous

3 months

Trial in people without random groups

Hodsman 2003

0.02 to 2.0 micrograms.kg-1

Human

human

subcutaneous

single dose

Trial in people without random groups

Schwietert 1997

2.0 to 5.0 micrograms.kg-1

Human

human

subcutaneous

single dose

Trial in people without random groups

Schwietert 1997

>2.5 micrograms.kg-1

Human

human

subcutaneous

single dose

Trial in people without random groups

Schwietert 1997

> or = 1.5 micrograms.kg-1

Human

human

subcutaneous

single dose

Trial in people without random groups

Schwietert 1997

0.02 to 5.0 micrograms.kg-1

Human

human

subcutaneous

single dose

Trial in people without random groups

Schwietert 1997

100 µg once daily

Human

human

Not reported

36 months

Trial in people without random groups

Zanchetta 2010

100 mug/d

Human

human

subcutaneous

1 yr

Observational study · n = 119

Bauer 2006

100 microg/kg/day, 5 days/week

Animal

rat

Not reported

Study in live animals · n = 12

Rhee 2004

1.1, 3.3, 10, or 30 nmol/kg/day

Animal

rat

Not reported

30 days

Study in live animals

Ejersted 1993

10, 50, 150 microg/kg/day

Animal

rat

subcutaneous

2 years

Study in live animals

Jolette 2006

50 and 150 microg/kg/day

Animal

rat

subcutaneous

2 years

Study in live animals

Jolette 2006

Context

Route

Amount

How often

How long

Agreement

Sources

Historical Natpara initiation in adults with hypoparathyroidism inadequately controlled with calcium and active vitamin D aloneOfficial label dosing of an approved product

subcutaneous injectionInject into the thigh. Alternate thighs each day.

50 mcg per dose

once daily

Not stated

Single official US label source.

PTH 1-84 (parathyroid hormone)

PTH 1-84 (parathyroid hormone) at a glance

What is parathyroid hormone?

The history of parathyroid hormone

PTH 1-84 (parathyroid hormone) structure and chemistry

What parathyroid hormone studies show

Bones and joints

Salt, water and minerals

Daily life and fitness

Kidneys and bladder

Hormones

Blood sugar

Key parathyroid hormone studies

PTH 1-84 clinical trials

Is parathyroid hormone approved?

PTH 1-84 side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about parathyroid hormone

Related peptides

Sources

PTH 1-84 (parathyroid hormone)

PTH 1-84 (parathyroid hormone) at a glance

What is parathyroid hormone?

The history of parathyroid hormone

PTH 1-84 (parathyroid hormone) structure and chemistry

What parathyroid hormone studies show

Bones and joints

Salt, water and minerals

Daily life and fitness

Kidneys and bladder

Hormones

Blood sugar

Key parathyroid hormone studies

PTH 1-84 clinical trials

Is parathyroid hormone approved?

PTH 1-84 side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Status notes

Community sources

Ask a question about parathyroid hormone

Related peptides

Sources